I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Sep 2020 - 25 Sep 2020

Human Studies, Pharmacology/Drug Development


2020 Sep 17

Qual Life Res

Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.


Ford JH, Stauffer VL, McAllister P, Akkala S, Sexson M, Ayer DW, Wang S
Qual Life Res. 2020 Sep 17.
PMID: 32944843.


Migraine can negatively impact patient functioning and quality of life. Here, we report the effects of galcanezumab (GMB), a humanized monoclonal antibody that binds to calcitonin gene-related peptide, on patient-reported outcome (PRO) measures in migraine.